CEFQUINOR LC Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

cefquinor lc

norbrook laboratories (ireland) limited rossmore industrial estate monaghan irska proizvajalec odgovoren za sproščanje serij: norbrook laboratories limited -

Hulio Evropska unija - slovenščina - EMA (European Medicines Agency)

hulio

biosimilar collaborations ireland limited - adalimumab - hidradenitis suppurativa; psoriasis; uveitis; arthritis, rheumatoid; spondylitis, ankylosing; crohn disease; colitis, ulcerative; arthritis, psoriatic - imunosupresivi, faktor tumorske nekroze alfa (tnf-α) inhibitorji

Silodosin Recordati Evropska unija - slovenščina - EMA (European Medicines Agency)

silodosin recordati

recordati ireland ltd - silodozin - hiperplazija prostate - urologicals, alfa-adrenoreceptor antagonisti - zdravljenje znakov in simptomov benigna hiperplazija prostate (bhp) pri odraslih moških.

Hepcludex Evropska unija - slovenščina - EMA (European Medicines Agency)

hepcludex

gilead sciences ireland uc - bulevirtide acetate - hepatitis d, chronic - antivirusi za sistemsko uporabo - hepcludex is indicated for the treatment of chronic hepatitis delta virus (hdv) infection in plasma (or serum) hdv-rna positive adult patients with compensated liver disease.

Xenleta Evropska unija - slovenščina - EMA (European Medicines Agency)

xenleta

nabriva therapeutics ireland dac - lefamulin acetate - pneumonia, bacterial; community-acquired infections - antibacterials za sistemsko uporabo, - xenleta is indicated for the treatment of community-acquired pneumonia (cap) in adults when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of cap or when these have failed. upoštevati je treba uradne smernice za ustrezno uporabo protibakterijsko agenti.

Livogiva Evropska unija - slovenščina - EMA (European Medicines Agency)

livogiva

theramex ireland limited - teriparatid - osteoporoza - kalcij homeostaza - livogiva is indicated in adults. zdravljenje osteoporoze pri ženskah po menopavzi in pri moških z večjim tveganjem zloma. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated. zdravljenje osteoporoze, povezane s trajno sistemsko glukokortikoidnih terapija pri ženskah in moških na povečano tveganje za zlom.